From time to time we use our own capital to make strategic investments in companies that fall outside our managed funds’ scope of interest. These investments are targeted at situations where our team is well positioned to have an especially high impact – frequently because of our special expertise and almost always because of our network of relationships throughout the industry. When making these kinds of investments, we seek out opportunities where members of our team can be involved in the startup (or even pre-startup) phase of the portfolio company’s life.


January 5, 2017 – Amplyx Pharmaceuticals Appoints Ciara Kennedy, Ph.D., as President and Chief Executive Officer

November 16, 2016 – FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections

September 12, 2016 – Amplyx Pharmaceuticals Initiates Dosing in Phase 1 Clinical Trial of APX001, a Novel Antifungal Product Candidate for Treatment of Life-Threatening Infections

February 9, 2016 – Amplyx Pharmaceuticals Expands Management Team and Increases Its Series B Financing to $49.2 Million


November 11, 2015 – Amplyx Pharmaceuticals Secures $40.5 million in Series B Financing

September 24, 2015 – Intarcia Therapeutics Announces Acquisition of Phoundry Pharmaceuticals

August 18, 2015 – New Peptide Company Phoundry Closes First Seed Funding